These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 10754727)

  • 1. The scientific basis for visible particle inspection.
    Knapp JZ
    PDA J Pharm Sci Technol; 1999; 53(6):291-302. PubMed ID: 10754727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Absolute" sterility and "absolute" freedom from particle contamination.
    Knapp JZ
    PDA J Pharm Sci Technol; 1998; 52(4):173-81. PubMed ID: 9752713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origin, result and measurement of USP "essentially free" inspection for visible contaminating particles.
    Knapp JZ
    PDA J Pharm Sci Technol; 2000; 54(3):218-32. PubMed ID: 10927913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving "Zero" Defects for Visible Particles in Injectables.
    Johns J; Golfetto P; Bush T; Fantozzi G; Shabushnig J; Perry A; Degrazio F; Streich D; Miller J; Soukiassian H; Stanton A; Watson R
    PDA J Pharm Sci Technol; 2018; 72(6):640-650. PubMed ID: 30232141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection.
    Melchore JA; Berdovich D
    PDA J Pharm Sci Technol; 2012; 66(3):273-84. PubMed ID: 22634593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
    Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M
    PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the forthcoming PDA task force report on the inspection for visible particles in parenteral products: practical answers for present problems.
    Knapp JZ
    PDA J Pharm Sci Technol; 2003; 57(2):131-9. PubMed ID: 14674515
    [No Abstract]   [Full Text] [Related]  

  • 9. Raman microscopic applications in the biopharmaceutical industry: in situ identification of foreign particulates inside glass containers with aqueous formulated solutions.
    Cao X; Wen ZQ; Vance A; Torraca G
    Appl Spectrosc; 2009 Jul; 63(7):830-4. PubMed ID: 19589222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated particulate inspection systems: strategies and implications.
    Knapp JZ; Abramson LR
    J Parenter Sci Technol; 1990; 44(2):74-107. PubMed ID: 2338607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conducting Clinical Risk Assessments for Visible Particulate Matter in Parenteral Preparations.
    Ayres JD
    PDA J Pharm Sci Technol; 2018; 72(6):626-639. PubMed ID: 30158238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new coincidence model for single particle counters, Part II: Advances and applications.
    Knapp JZ; Lieberman A; Abramson LR
    PDA J Pharm Sci Technol; 1994; 48(5):255-92. PubMed ID: 8000900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach.
    Langille SE
    PDA J Pharm Sci Technol; 2020; 74(3):359-366. PubMed ID: 31732691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of Visible Particles in Parenteral Products by Manual Visual Inspection-Reassessing Size Threshold and Other Particle Characteristics that Define Particle Visibility.
    Mazaheri M; Saggu M; Wuchner K; Koulov AV; Nikels F; Chalus P; Das TK; Cash PW; Finkler C; Levitskaya-Seaman SV; Case J; Parsons J; Gonzalez K
    J Pharm Sci; 2024 Mar; 113(3):616-624. PubMed ID: 37802369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Risk- and Science-Based Approach to the Acceptance Sampling Plan Inspection of Protein Parenteral Products.
    Spasoff A; Bennis A; Atkinson S; Elliott C; Freund E; Narhi L
    J Pharm Sci; 2018 Sep; 107(9):2306-2309. PubMed ID: 29859961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new coincidence model for single particle counters, Part I: Theory and experimental verification.
    Knapp JZ; Abramson LR
    J Pharm Sci Technol; 1994; 48(3):110-34. PubMed ID: 8069513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing Patient Safety through the Use of a Pharmaceutical Glass Designed To Prevent Cracked Containers.
    Schaut RA; Hoff KC; Demartino SE; Denson WK; Verkleeren RL
    PDA J Pharm Sci Technol; 2017; 71(6):511-528. PubMed ID: 28928290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing Cross-Contamination during Lyophilization: GMP and Occupational Cleaning Requirements for Nonproduct and Indirect Product-Contact Parts.
    Denk R; Flückiger A; Kisaka H; Krause S; Maeck R; Restetzki L; Schreiner A; Schulze R
    PDA J Pharm Sci Technol; 2019; 73(5):487-495. PubMed ID: 31420508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.